Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRETTO-531 selpercatinib versus cabozantinib or vandetanib in RET-mutant medullary thyroid cancer
2023-506782-56-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial in Medullary Thyroid Cancer (MTC) comparing Selpercatinib with Physician's choice: cabozantinib or vandetanib (2 arms). Primary endpoint: Progression-free survival by blinded independent central review. Planned start Mar 2020; status: authorised.
02
Drugs
selpercatinibcabozantinibvandetanib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on 2023-506782-56-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506782-56-00.